Medicine and Dentistry
Patient
93%
Amyotrophic Lateral Sclerosis
38%
Inpatient
37%
Antibody
25%
Neuromyelitis Optica
24%
Motor Evoked Potential
24%
Myelin Oligodendrocyte Glycoprotein
23%
Diagnosis
23%
Aquaporin 4
20%
Monitoring
20%
Surgery
19%
Spine Surgery
17%
Disease
17%
Immunoglobulin G
15%
Optic Neuritis
15%
Lesion
14%
Multiple Sclerosis
11%
Rituximab
10%
Neuroprotective Agent
10%
Myasthenia gravis
10%
Electromyography
10%
Muscle
10%
Combination Therapy
9%
Accuracy
9%
Prognosis
8%
Aquaporin 4 Antibody
8%
Assessment
8%
Adult
8%
Symptom
8%
Neuropathy
7%
Noninvasive Ventilation
7%
Magnetic Resonance Imaging
7%
Cognitive Defect
7%
Interstitial Lung Disease
6%
Facial Nerve Paralysis
6%
Frontal Lobe
6%
Leg Muscle
6%
Intermittent Hypoxia
6%
Glycyrrhizic Acid
6%
Intraoperative Neurophysiological Monitoring
6%
Reproducibility
6%
Fatigue
6%
Capnography
6%
Hypoventilation
6%
Eculizumab
6%
Muscle Atrophy
6%
Hemifacial Spasm
6%
Health
6%
Clinically Isolated Syndrome
6%
Recurrent Disease
6%
Neuroscience
Neuromyelitis Optica
100%
Amyotrophic Lateral Sclerosis
52%
Spectrum Disorder
46%
Multiple Sclerosis
29%
Aquaporin 4 Antibody
29%
Immunoglobulin G
19%
Rituximab
18%
Aquaporin 4
17%
Spinal Cord
16%
Antibodies
16%
Myelin Oligodendrocyte Glycoprotein
15%
Transverse Myelitis
13%
Neuroprotective Agent
12%
Cognitive Disorders
11%
Motor Neuron
11%
SOD1
10%
Optic Neuritis
10%
Brain Abnormalities
8%
Central Nervous System
8%
Demyelinating Disease
8%
Hypertension
8%
Optic Nerve
7%
Myelitis
7%
Cholesterol Derivative
7%
Complement Dependent Cytotoxicity
7%
Cerebral Amyloid Angiopathy
6%
25 Hydroxycholesterol
6%
Brain Tumor
6%
Glycyrrhizic Acid
6%
Complement Component C1q
6%
Oxidative Stress
6%
Motor Evoked Potential
6%
Nystagmus
6%
Motor Unit
6%
Brain
5%
Steroids
5%
Immunology and Microbiology
Neuromyelitis Optica
29%
Myelin Oligodendrocyte Glycoprotein
19%
Multiple Sclerosis
12%
Monospecific Antibody
10%
Immunoglobulin G
10%
Aquaporin 4 Antibody
10%
Spectrum
8%
Optic Neuritis
8%
Association
7%
Rituximab
7%
Cells
7%
Cerebrospinal Fluid
6%
Astrocyte
6%
Eculizumab
6%
Myasthenia gravis
6%